Drug intelligence / Profile preview

RO-7

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules

Overview

RO-7 is an investigational small molecule identified as a next-generation polymerase (PA) endonuclease inhibitor, specifically targeting influenza A and B viruses. This compound potently inhibits viral replication and belongs to a new class of drugs in late-stage clinical trials for the treatment of influenza virus infection. Preclinical studies have demonstrated its broad-spectrum anti-influenza activity in vitro and its ability to protect mice from lethal influenza A and B challenges.

Targets

CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)

Beyond the preview

Go deeper on RO-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO-7.

Explore the full profile